Profiling the effects of repetitive morphine administration on motor behavior in rats

Efficient repetitive clinical use of morphine is limited by its numerous side effects, whereasanalgesic tolerance necessitates subsequent increases in morphine dose to achieve adequate levelsof analgesia. While many studies focused on analgesic tolerance, the effect of morphine dosing onnon-analgesic effects has been overlooked. This study aimed to characterize morphine-inducedbehavior and the development and progression of morphine-induced behavioral tolerance. Adultmale Sprague–Dawley rats were repetitively treated with subcutaneous morphine for 14 days in twodose groups (A: 5 mg/kg/day (b.i.d.) → 10 mg/kg/day; B: 10 mg/kg/day (b.i.d.) → 20 mg/kg/day).Motor behavior was assessed daily (distance traveled, speed, moving time, rearing, rotation) in anopen-field arena, before and 30 min post-injections. Antinociception was measured using tail-flickand hot-plate assays. All measured parameters were highly suppressed in both dosing groups onthe first treatment day, followed by a gradual manifestation of behavioral tolerance as the treatmentprogressed. Animals in the high-dose group showed increased locomotor activity after 10 days ofmorphine treatment. This excitatory phase converted to an inhibition of behavior when a highermorphine dose was introduced. We suggest that the excitatory locomotor effects of repetitive highdose morphine exposure represent a signature of its behavioral and antinociceptive tolerance

Data on prolonged morphine-induced antinociception and behavioral inhibition in older rats

This article contains supportive data related to a research article entitled “Age-dependent antinociception and behavioral inhibition by morphine” (Paul et al., 2018) [1]. Antinociceptive latencies of 8 and 24-week old rats were obtained from tail-flick and hot plate assays after morphine treatment. Motor behavioral effects were measured at different time-points using automated infrared tracking in an open-field arena. Residual morphine content in post-mortem tissues were measured 240 min post-treatment. Concurrent measurements of antinociception, motor behavior and residual morphine content in post-mortem tissues of 8-week and 24-week old morphine-treated rats provide an integrated assessment of age-related differences

Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile

Opioid receptors are currently classified as mu (mu: mOP), delta (delta: dOP), kappa (kappa: kOP) with a fourth related non-classical opioid receptor for nociceptin/orphainin FQ, NOP. Morphine is the current gold standard analgesic acting at MOP receptors but produces a range of variably troublesome side-effects, in particular tolerance. There is now good laboratory evidence to suggest that blocking DOP while activating MOP produces analgesia (or antinociception) without the development of tolerance. Simultaneous targeting of MOP and DOP can be accomplished by: (i) co-administering two selective drugs, (ii) administering one non-selective drug, or (iii) designing a single drug that specifically targets both receptors; a bivalent ligand. Bivalent ligands generally contain two active centres or pharmacophores that are variably separated by a chemical spacer and there are several interesting examples in the literature. For example linking the MOP agonist oxymorphone to the DOP antagonist naltrindole produces a MOP/DOP bivalent ligand that should produce analgesia with reduced tolerance. The type of response/selectivity produced depends on the pharmacophore combination (e.g. oxymorphone and naltrindole as above) and the space between them. Production and evaluation of bivalent ligands is an emerging field in drug design and for anaesthesia, analgesics that are designed not to be highly selective morphine-like (MOP) ligands represents a new avenue for the production of useful drugs for chronic (and in particular cancer) pain

Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.

Opioid receptors are currently classified as mu (mu: mOP), delta (delta: dOP), kappa (kappa: kOP) with a fourth related non-classical opioid receptor for nociceptin/orphainin FQ, NOP. Morphine is the current gold standard analgesic acting at MOP receptors but produces a range of variably troublesome side-effects, in particular tolerance. There is now good laboratory evidence to suggest that blocking DOP while activating MOP produces analgesia (or antinociception) without the development of tolerance. Simultaneous targeting of MOP and DOP can be accomplished by: (i) co-administering two selective drugs, (ii) administering one non-selective drug, or (iii) designing a single drug that specifically targets both receptors; a bivalent ligand. Bivalent ligands generally contain two active centres or pharmacophores that are variably separated by a chemical spacer and there are several interesting examples in the literature. For example linking the MOP agonist oxymorphone to the DOP antagonist naltrindole produces a MOP/DOP bivalent ligand that should produce analgesia with reduced tolerance. The type of response/selectivity produced depends on the pharmacophore combination (e.g. oxymorphone and naltrindole as above) and the space between them. Production and evaluation of bivalent ligands is an emerging field in drug design and for anaesthesia, analgesics that are designed not to be highly selective morphine-like (MOP) ligands represents a new avenue for the production of useful drugs for chronic (and in particular cancer) pain